10-Q quarterly report · filed Nov 5, 2026

Keros Therapeutics, Inc. (KROS) Q3 2026 10-Q Quarterly Report

Short answer

Keros Therapeutics, Inc. (KROS) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $40M (up 180.5% year over year) with net income of $14M.

Q3 2026 key financials · XBRL

Revenue
$40M
+180.5% YoY
Net income
$14M
+294.4% YoY · +149.3% QoQ
Operating margin
32.0%
EPS (diluted)
$0.72
+500.0% YoY · +149.7% QoQ

Source: XBRL data from the Keros Therapeutics, Inc. (KROS) Q3 2026 10-Q on SEC EDGAR. USD.

Keros Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $40.0M, up $25.7M YoY from $14.3M, driven by Takeda milestones
  • Net income $14.2M vs $7.3M loss YoY, operating margin 32.0% vs negative 107.9%
  • Rinvatercept R&D $5.0M, up $3.7M YoY, best-performing pipeline line
  • Cash $259.5M; operating cash flow $(20.6)M vs $134.8M YoY
  • Cash runway into second half of 2028; inflation, tariffs and capital-market volatility headwinds

Risk Factors

  • Regulatory risk: EU Pharma Package could reduce orphan exclusivity from 10 to 9 years, accelerating generic or biosimilar competition
  • Financial risk: $259.5 million cash and cash equivalents expected to fund operations into the second half of 2028
  • Clinical risk: Cibotercept TROPOS trial terminated after unanticipated pericardial effusion adverse events
  • Competitive risk: DMD competition expanded following Sarepta, Avidity Biosciences and Edgewise Therapeutics developments
  • Compliance risk: UK clinical-trial amendments effective April 28, 2026 may increase CRO compliance costs and delay trial initiation

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Keros Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.